Latest News-Ascletis Pharma Inc. Mediaroom_Page

Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study

HANGZHOU and SHAOXING, China, Dec. 4, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) announc...

2020-12-04 08:00 4043

Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer

SHANGHAI, Nov. 30, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2020-11-30 08:00 3163

ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China

SHANGHAI and SAN FRANCISCO, Nov. 19, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned c...

2020-11-19 08:30 3211

Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH

HANGZHOU, China and SHAOXING, China, Nov. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code...

2020-11-18 17:00 7088

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist

SHANGHAI, Oct. 12, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis...

2020-10-12 08:30 8768

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist

SHANGHAI, Oct. 11, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis...

2020-10-12 08:30 7862

Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist

SHANGHAI, Sept. 14, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascleti...

2020-09-14 08:30 3859

Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)

SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owne...

2020-09-09 18:30 4972

Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen

HANGZHOU and SHAOXING, China, Aug. 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-08-20 20:00 4184

First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody

HANGZHOU, China and SHAOXING, China, Aug. 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2020-08-17 08:30 4047

Ascletis' All-oral HCV Treatment Approved for Marketing in China

HANGZHOU and SHAOXING, China, July 31, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-07-31 08:47 10064

Bridging Study in China Completed for NASH Drug Candidate ASC40

HANGZHOU and SHAOXING, China, July 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-07-20 08:30 4926

ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial

HANGZHOU, China and SHAOXING, China, June 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2020-06-17 20:30 3345

Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication

HANGZHOU, China and SHAOXING, China, May 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: ...

2020-05-13 18:30 3122

Ascletis Receives IND Approval for its HIV Drug ASC09F

HANGZHOU and SHAOXING, China, April 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672)...

2020-04-13 20:00 3640

Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020

HANGZHOU and SHAOXING, China, April 1, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-04-01 08:30 2966

Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients

HANGZHOU and SHAOXING, China, March 25, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672)...

2020-03-25 08:28 3387

Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia

HANGZHOU, China and SHAOXING, China, March 10, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code...

2020-03-10 17:30 4031

Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia

HANGZHOU and SHAOXING, China, Feb. 27, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) ...

2020-02-27 08:00 4061

Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA

HANGZHOU, China and SHAOXING, China, Feb. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2020-02-18 08:00 3436